Skip to main
  1. Stocks
  2. Krystal Biotech
  3. Forecast
KRYS

Krystal Biotech (KRYS) Stock Forecast & Price Target

Krystal Biotech (KRYS) Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Krystal Biotech is well positioned fundamentally because VYJUVEK continues to compound, with Q3 worldwide revenue of $127 million, net profit of $63 million, gross margins of 94%, and over 760 U.S. reimbursement approvals, while ex-U.S. uptake is gaining traction in Germany, Italy, and Japan. Its outlook is further strengthened by a very strong balance sheet with $1.2 billion in cash, lower FY26 non-GAAP OpEx guidance of $155 million to $165 million, and a planned $400 million buyback, signaling both profitability and capital discipline. Beyond the core franchise, the patented HSV-1 platform is producing multiple shots on goal in NK, ocular DEB, CF, HHD, AATD, and oncology, with early efficacy and tolerability signals that could create meaningful long-term upside if later-stage data confirm benefit.

Bears say

Krystal Biotech is facing a weaker fundamental setup because multiple key clinical programs have slipped on enrollment, pushing Ph3 '801 and '407 and Ph3 '803 into 1H27 or later 2027, while EMERALD-1 now guides to 2027 data after slower-than-expected site activation and patient hesitancy. Although Q3 net Vyjuvek revenue of $127M and EPS of $2.05 met consensus, growth is being pressured by ex-U.S. launch frictions, including France’s hospital-based GMO administration, Japan’s twice-monthly represcribing requirement, and Italy’s delayed launch into early 2027. These delays reduce near-term visibility and increase execution risk across clinical, regulatory, and commercialization fronts, limiting confidence that the company can sustain the trajectory needed to meet longer-term financial projections.

Krystal Biotech (KRYS) has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Krystal Biotech and is not a guaranteed prediction by Public.com or investment advice.

Krystal Biotech (KRYS) Analyst Forecast & Price Prediction

Get the latest Krystal Biotech (KRYS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Krystal Biotech (KRYS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Krystal Biotech (KRYS) Forecast

Analysts have given Krystal Biotech (KRYS) a Strong Buy based on their latest research and market trends.

According to 10 analysts, Krystal Biotech (KRYS) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $364.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $364.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Krystal Biotech (KRYS)


Krystal Biotech (KRYS) Analyst Forecast & Price Prediction

Get the latest Krystal Biotech (KRYS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Krystal Biotech (KRYS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover KRYS stock data and trends